Friedreich ataxia is a rare, inherited, neurodegenerative disorder that affects the nervous system, resulting in progressive physical and cognitive disability. It is estimated to affect approximately 1 in 50,000 people worldwide. It is caused by a mutation in a gene called FXN, which is responsible for producing a protein called frataxin. Frataxin is essential for healthy cell function in the body, and when it is missing, cells cannot perform their normal functions, leading to the symptoms of Friedreich ataxia. This article will provide an overview of Friedreich ataxia, including its causes, symptoms, diagnosis, and treatments.
Friedreich ataxia is an inherited disorder that affects the nervous system and causes progressive physical and cognitive disability. It is caused by a mutation in the FXN gene, which is responsible for producing a protein called frataxin. Frataxin is essential for healthy cell function in the body, and when it is missing, cells cannot perform their normal functions, leading to the symptoms of Friedreich ataxia.
The symptoms of Friedreich ataxia vary from person to person, but usually appear in childhood or adolescence. Common symptoms include: • Progressive loss of coordination, balance, and muscle strength • Loss of sensation in the extremities • Slurred speech and difficulty swallowing • Vision problems • Hearing loss • Heart problems • Fatigue • Scoliosis • Diabetes
Friedreich ataxia is caused by a mutation in the FXN gene, which is responsible for producing a protein called frataxin. Frataxin is essential for healthy cell function in the body, and when it is missing, cells cannot perform their normal functions, leading to the symptoms of Friedreich ataxia.
Friedreich ataxia is usually diagnosed through a combination of physical examination, neurological testing, and genetic testing. Physical examination may reveal signs of muscle weakness, coordination problems, and scoliosis. Neurological testing may reveal impaired reflexes, muscle weakness, and balance problems. Genetic testing can confirm the presence of the FXN gene mutation.
There is currently no cure for Friedreich ataxia, but there are treatments available to help manage the symptoms. Treatment may include physical therapy, occupational therapy, speech therapy, and medications to help manage pain, fatigue, and other symptoms. Additionally, there are clinical trials underway to investigate potential treatments for Friedreich ataxia.
Friedreich ataxia is a rare, inherited, neurodegenerative disorder that affects the nervous system, resulting in progressive physical and cognitive disability. It is caused by a mutation in a gene called FXN, which is responsible for producing a protein called frataxin. Diagnosis involves physical examination, neurological testing, and genetic testing, and treatments may include physical therapy, occupational therapy, speech therapy, and medications. While there is currently no cure for Friedreich ataxia, there are treatments available to help manage the symptoms and clinical trials underway to investigate potential treatments.
1.
The use of biomarkers in the treatment of breast lumps is at a crossroads.
2.
According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.
3.
How Do Younger People Fare With Stool Tests for CRC Screening?
4.
Dual Targeted CAR-T Yields 99% Response Rate in Pediatric ALL
5.
Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer
1.
How Parvovirus B19 Affects Pregnant Women and Their Unborn Babies
2.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
3.
Introduction to Immune Thrombocytopenic Purpura
4.
Unveiling the Chadwick Sign: A Revolutionary New Tool for Detecting Early Signs of Cancer
5.
The Different Types of Cysts and Why They Occur: Insights from a Dermatologist
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment
2.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
3.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
4.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
5.
Navigating the Complexities of Ph Negative ALL - Part XII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation